Dongfeng Zhao

Dongfeng Zhao

Auto-generated profile, based on publicly available information

Dongfeng Zhao

Longhua Hospital University of Traditional Chinese Medicine at Shanghai Shanghai China

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2019 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
DZDongfeng Zhao
Dongfeng Zhao
BSBing Shu
Bing Shu
CWChenglong Wang
Chenglong Wang
YZYongjian Zhao
Yongjian Zhao
WCWeidong Cheng
Weidong Cheng
YWYong-jun Wang
Yong-jun Wang

17 July 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
DZDongfeng Zhao
Dongfeng Zhao
ZSZhenqi Shi
Zhenqi Shi
AWAmy H. Warriner
Amy H. Warriner
PQPing Qiao
Ping Qiao
HHHuixian Hong
Huixian Hong
XFXu Feng
Xu Feng
Thiazolidinediones are synthetic peroxisome proliferator-activated receptor γ agonists used to treat type 2 diabetes mellitus. Clinical evidence indicates that thiazolidinediones increase fracture risks in type 2 diabetes mellitus patients, but the mechanism by which thiazolidinediones augment fracture risks is not fully understood. Several groups recently demonstrated that thiazolidinediones stimulate osteoclast formation, thus proposing that thiazolidinediones induce bone loss in part by prompting osteoclastogenesis. However, numerous other studies showed that thiazolidinediones inhibit osteoclast formation. Moreover, the molecular mechanism by which thiazolidinediones modulate osteoclastogenesis is not fully understood. Here we independently address the role of thiazolidinediones in osteoclastogenesis in vitro and furthermore investigate the molecular mechanism underlying the in vitro effects of thiazolidinediones on osteoclastogenesis. Our in vitro data indicate that thiazolidinediones dose-dependently inhibit osteoclastogenesis from bone marrow macrophages, but the inhibitory effect is considerably reduced when bone marrow macrophages are pretreated with RANKL. In vitro mechanistic studies reveal that thiazolidinediones inhibit osteoclastogenesis not by impairing RANKL-induced activation of the NF-κB, JNK, p38 and ERK pathways in bone marrow macrophages. Nonetheless, thiazolidinediones inhibit osteoclastogenesis by suppressing RANKL-induced expression of NFATc1 and c-Fos, two key transcriptional regulators of osteoclastogenesis, in bone marrow macrophages. In addition, thiazolidinediones inhibit the RANKL-induced expression of osteoclast genes encoding matrix metalloproteinase 9, cathepsin K, tartrate-resistant acid phosphatase and carbonic anhydrase II in bone marrow macrophages. However, the ability of thiazolidinediones to inhibit the expression of NFATc1, c-Fos and the four osteoclast genes is notably weakened in RANKL-pretreated bone marrow macrophages. These in vitro studies have not only independently demonstrated that thiazolidinediones exert inhibitory effects on osteoclastogenesis but have also revealed crucial new insights into the molecular mechanism by which thiazolidinediones inhibit osteoclastogenesis.

25 November 2019 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
DZDongfeng Zhao
Dongfeng Zhao
BSBing Shu
Bing Shu
CWChenglong Wang
Chenglong Wang
YZYongjian Zhao
Yongjian Zhao
WCWeidong Cheng
Weidong Cheng
YWYong-jun Wang
Yong-jun Wang